COBRE Center for Lung Biology Research

Lung disease is the third most frequent cause of death in this country, claiming ~360,000 Americans annually. Tragically, an additional 25 million live with chronic lung diseases including asthma, emphysema, cancer and cystic fibrosis. Unfortunately, the number of individuals with lung disease is increasing at an alarming rate, thus, a better understanding of the etiology of lung disease and new therapeutics to treat lung disease are required.

The goals of the Dartmouth Lung Biology Center, funded by a COBRE award by the NCRR since 2003 (P20-RR01878), are to enhance the research efforts of our faculty and students by:

  1. integration of the COBRE supported Proteomics and Imaging Core with shared services of other DMS and DHMC Cores including Bioinformatics and Biostatistics;
  2. fostering synergistic scientific collaboration through the four COBRE Research Projects, associated Cores, and other basic and translational infrastructure and programs at DMS/DHMC;
  3. mentoring and supporting the career development of all faculty in the program, and;
  4. providing administrative support.

The four COBRE/Center funded projects are:

Project 1 - Molecular Mechanisms of Aurora Kinase A Dysfunction in Lung Cancer Principal Investigator: Scott Gerber, Ph.D., Assistant Professor of Genetics

Project 2 - A Novel Regulator of P. Aeruginosa Virulence Genes Principal Investigator: Deborah Hogan, Ph.D., Assistant Professor of Microbiology and Immunology

Project 3 - Humanizing Alginate Depolymerase: New Strategies for De-immunizing Enzyme Therapies Principal Investigator: Karl Griswold, Ph.D., Assistant Professor of Engineering

Project 4 - Biodiesel and Petroleum Diesel: Exposure Profiles and Public Health Consequences Principal Investigator: Nora Traviss, Ph.D., Assistant Professor, Keene State College

The Center also funds, with support by a Cystic Fibrosis Foundation Research Development Program award, seven pilot and feasibility projects:

P&F Project 1 - Phagocytic Mechanisms of Pseudomonas Clearance within the CF lung
Principal Investigator: Brent Berwin, Ph.D., Assistant Professor of Microbiology and Immunology

P&F Project 2 - Dampening Airway Inflammation by Silencing IL-8 with Poorly Immunogenic siRNA Nanocarriers
Principal Investigator: Dr. Jose Conejo-Garcia, Assistant Professor of Microbiology and Immunology

P&F Project 3 - Rapid Identification of Pathogens found in the CF Lung
Principal Investigator: Dr. Jane Hill, Assistant Professor of Engineering, University of Vermont

P&F Project 4 - Evaluation of Iron-Related Hematologic Parameters in Adult Patients with Cystic Fibrosis
Principal Investigators: Dr. Worth Parker, Associate Professor of Medicine and Dr. Alex Gifford, Senior Fellow in Medicine

P&F Project 5 - Novel Drug Discovery Approaches in CF
Principal Investigator: Dr. Dean Madden, Professor of Biochemistry

P&F Project 6 - The CF Lung Microbiome-Deep Sequencing
Principal Investigator: Dr. George O'Toole, Associate Professor of Microbiology and Immunology

P&F Project 7 - The CF Gut Microbiome, Deep Sequencing
Principal Investigator: Dr. Juliette Madan, Assistant Professor of Pediatrics

News

Lung Biology Resercher, Steve Bernier Ph.D., has been awarded a two-year Kin Canada Fellowship from the Canadian Cystic Fibrosis Foundation

March 12 2010

Steve Bernier, Ph.D. was awarded a two-year Kin Canada Fellowship from the Canadian Cystic Fibrosis Foundation and a travel award to attend the Young Investigators Forum in Circulatory and Respiratory Health held in Vancouver. The Kin Canada Fellowship award given each year to the postdoctoral fellow who writes the number one rated application.

The CCFF Kin Canada Fellowship is awarded to a candidate with high standing in the Foundation's annual awards competition who: 1) demonstrates potential for a career in a research area related to cystic fibrosis, 2) is engaged in research in a prominent field of CF investigation, and 3) is pursuing his/her postdoctoral studies in a laboratory of outstanding training potential.

Vertex Announces Results from Phase 2a Trial of VX-809, a CFTR corrector

February 4,2010

Vertex Pharmaceuticals announced results from a 28-day Phase 2a clinical trial of VX-809 in patients with CF homozygous for the F508del mutation. VX-809, an oral investigational CFTR corrector, was well-tolerated across all four dose groups studied and produced a dose response reduction in sweat chloride across the four dose groups. Vertex plans to initiate a combination trial of VX-809 and VX-770 (a potentiator) in the second half of 2010. For more information go to: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=442429

A recent manuscript by George O'Toole and his former fellow Greg Anderson describes the role of a Mg transporter in controlling virulence of P. aeruginosa

February 2, 2010

The title of the article is: The Pseudomonas aeruginosa Magnesium Transporter MgtE Inhibits Transcription of the Type III Secretion System. Anderson GG, Yahr TL, Lovewell RR, O'Toole GA. Infect Immun. 2009 Dec 22. [Epub ahead of print]PMID: 20028803.

To view the abstract for this article use this link: Abstract

Events

3rd Annual Integrative Biology Symposium - Translational Science

February 4, 2010

To be held from April 27-28, 2010 at Alumni Hall, Dartmouth College, Hanover, NH. The symposium will include speakers from Dartmouth College, several outside speakers, and a student poster session.

Weekly Meeting Schedule

October 23, 2009

The Lung Biology Weekly Meetings have resumed for the fall term. The meetings are on Wednesdays from 8am - 9am in Vail 202. The full schedule can be viewed here.